Grifols

Grifols, a pharmaceutical preparation manufacturing company headquartered in Spain, has outlined ambitious climate commitments. For the reporting year 2025, Grifols reported a total of approximately 1.36 billion kg CO2e. This includes Scope 1 emissions totalling about 121.9 million kg CO2e, Scope 2 emissions of approximately 83.9 million kg CO2e (market-based), and substantial Scope 3 emissions amounting to approximately 1.15 billion kg CO2e.

In 2024, Grifols's total emissions were approximately 1.23 billion kg CO2e, with Scope 1 emissions at about 123.2 million kg CO2e, Scope 2 at around 166.1 million kg CO2e (market-based), and Scope 3 emissions at approximately 1.12 billion kg CO2e. The preceding year, 2023, saw total emissions of about 1.15 billion kg CO2e, comprising 124.8 million kg CO2e for Scope 1, 98.1 million kg CO2e for Scope 2 (market-based), and 998.3 million kg CO2e for Scope 3.

Grifols has set a target to achieve net-zero emissions by 2050 for Scopes 1 and 2. Furthermore, the company is committed to reducing absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030, using 2022 as the baseline year, aligning with Science Based Targets initiative (SBTi) recommendations. Additionally, Grifols aims to reduce absolute Scope 3 GHG emissions by 25% by 2030, also from a 2022 baseline, focusing on categories such as purchased goods and services, capital goods, fuel- and energy-related activities, and upstream transportation and distribution. Another near-term target involves a 55% reduction in GHG emissions per production unit by 2030, compared to 2018 levels. Grifols also plans to reduce its Scope 1 and Scope 2 emissions to near zero by the middle of the current decade.